IN8bio, Inc. Reports Q2 2026 Financial Results

What Happened

• On August 6, 2026, IN8bio, Inc. announced its financial results for the second quarter ended June 30, 2026 and furnished a press release as Exhibit 99.1 to a Form 8‑K (Item 2.02). The Form 8‑K itself references the press release for details. The report was signed by Patrick McCall, Chief Financial Officer and Secretary.

Key Details

• Announcement date: August 6, 2026.
• Reporting period: Quarter ended June 30, 2026.
• Disclosure format: Press release furnished as Exhibit 99.1 to the Form 8‑K (Item 2.02); cover page interactive XBRL file included (Exhibit 104).
• Authorized signature: /s/ Patrick McCall (CFO and Principal Financial and Accounting Officer).

Why It Matters

• This 8‑K is the company’s official disclosure that it has released quarterly earnings and other financial information for Q2 2026. Retail investors should review the Exhibit 99.1 press release (or the company’s investor relations page) for the actual revenue, earnings, cash position, and any commentary on operations or guidance, since the filing itself references but does not recite those figures. Updated quarterly results can influence valuation, analyst estimates, and short‑term trading decisions.